Publication date: Aug 05, 2024
The aim of this randomized multicentre phase 2 clinical trial is to compare the effects of rTMS and SSRI medication as early treatment of depression. In this two-stage, therapy response-adapted trial, 106 patients suffering from non-treatment resistant major depression (non-TR MD) will be randomized in Stage I to either 4 weeks bilateral theta burst stimulation (TBS) or 4 weeks antidepressant SSRI medication. The allocation to Stage II occurs therapy response-adapted. Patients receive either a maintenance treatment or a switch to the respective other treatment arm. The primary outcome is the comparison of the two study arms with regard to therapy response measured with the Montgomery-Asberg Depression Rating Scale (MADRS) after 4 weeks at the end of Stage I.
Concepts | Keywords |
---|---|
Benzodiazepines | Depression |
Mri | non-invasive brain stimulation |
Stage | non-treatment resistant depression |
Suicidal | theta burst stimulation |
Tbs |
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Serotonin |
drug | DRUGBANK | Tilmicosin |
disease | MESH | suicidal ideation |
drug | DRUGBANK | Lorazepam |
disease | MESH | anxiety disorders |
disease | MESH | personality disorder |
disease | MESH | neoplasms brain |
disease | MESH | stroke |
disease | MESH | neurodegenerative diseases |
disease | MESH | epilepsy |
disease | MESH | epileptic seizures |
disease | MESH | contraindications |
drug | DRUGBANK | Escitalopram |
disease | MESH | Major Depressive Disorder |
disease | MESH | treatment resistant depression |